Roland Kontermann
Overview
Explore the profile of Roland Kontermann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Katiyar P, Schwenck J, Frauenfeld L, Divine M, Agrawal V, Kohlhofer U, et al.
Nat Biomed Eng
. 2023 Jun;
7(8):1014-1027.
PMID: 37277483
In oncology, intratumoural heterogeneity is closely linked with the efficacy of therapy, and can be partially characterized via tumour biopsies. Here we show that intratumoural heterogeneity can be characterized spatially...
2.
Dilchert J, Hofmann M, Unverdorben F, Kontermann R, Bunk S
Antibodies (Basel)
. 2022 Jun;
11(2).
PMID: 35645207
Bispecific T cell receptor (TCR)-based molecules capable of redirecting and activating T cells towards tumor cells represent a novel and promising class of biotherapeutics for the treatment of cancer. Usage...
3.
Hartung F, Kruwel T, Shi X, Pfizenmaier K, Kontermann R, Chames P, et al.
Front Pharmacol
. 2020 Jun;
11:686.
PMID: 32528281
Antibody-based therapies hold promise for a safe and efficient treatment of cancer. The identification of target tumor cells through a specific antigen enriched on their surface and the subsequent delivery...
4.
Vetma V, Gutta C, Peters N, Praetorius C, Hutt M, Seifert O, et al.
Cell Death Differ
. 2020 Feb;
27(8):2417-2432.
PMID: 32081986
Second generation TRAIL-based therapeutics, combined with sensitising co-treatments, have recently entered clinical trials. However, reliable response predictors for optimal patient selection are not yet available. Here, we demonstrate that a...
5.
Puerto-Camacho P, Amaral A, Lamhamedi-Cherradi S, Menegaz B, Castillo-Ecija H, Ordonez J, et al.
Clin Cancer Res
. 2018 Nov;
25(7):2228-2240.
PMID: 30420447
Purpose: Endoglin (ENG; CD105) is a coreceptor of the TGFβ family that is highly expressed in proliferating endothelial cells. Often coopted by cancer cells, ENG can lead to neo-angiogenesis and...
6.
Williams S, Fairless R, Maier O, Liermann P, Pichi K, Fischer R, et al.
Sci Rep
. 2018 Sep;
8(1):13628.
PMID: 30206422
Tumour necrosis factor (TNF) signalling is mediated via two receptors, TNF-receptor 1 (TNFR1) and TNF-receptor 2 (TNFR2), which work antithetically to balance CNS immune responses involved in autoimmune diseases such...
7.
Sapski S, Beha N, Kontermann R, Muller D
Oncoimmunology
. 2017 Dec;
6(12):e1361594.
PMID: 29209565
Therapeutic strategies aiming for the induction of an effective immune response at the tumor site can be severely hampered by the encounter of an immunosuppressive microenvironment. We investigated here the...
8.
Moller Y, Morkel M, Schmid J, Beyes S, Hendrick J, Strotbek M, et al.
Oncotarget
. 2016 Jul;
7(33):53526-53539.
PMID: 27447549
Here we study the effects of inducible oncogenic K-Ras (G12V) expression on the polarized morphogenesis of colonic epithelial cells. We provide evidence that the autocrine production of heregulins, ligands for...
9.
Lindner R, Moosmann A, Dietrich A, Bottinger H, Kontermann R, Siemann-Herzberg M
J Biotechnol
. 2014 Dec;
192 Pt A:136-45.
PMID: 25450642
Prokaryotic production systems have been widely used to manufacture recombinant therapeutic proteins. Economically, the prokaryotic production – especially of small therapeutic molecules – is advantageous compared to eukaryotic production strategies....
10.
Moller Y, Siegemund M, Beyes S, Herr R, Lecis D, Delia D, et al.
PLoS One
. 2014 Sep;
9(9):e107165.
PMID: 25198428
TRAIL is a death receptor ligand that induces cell death preferentially in tumor cells. Recombinant soluble TRAIL, however, performs poorly as an anti-cancer therapeutic because oligomerization is required for potent...